Cipla, a prominent Indian pharmaceutical company, announced that it has entered into a licensing agreement with Novartis Pharma AG (Switzerland) to produce and market the Galvus range, which is used in the treatment of type 2 diabetes, effective from January 1, 2026.
Buy Prime Test Series for all Banking, SSC, Insurance & other exams
According to the regulatory filing, Cipla has signed a perpetual license agreement to manufacture and market Galvus and Galvus combination brands. The drug firm believes that this partnership will enhance its standing in the diabetes category and reinforce its position as one of the major players in the Indian market. The agreement is contingent upon the fulfillment of certain preconditions, as stated by Cipla. The Galvus brand is a prominent name in the Dipeptidyl Peptidase-4 (DPP4) space and a major player in the oral diabetic medication category, according to the drug firm. On the Bombay Stock Exchange (BSE), Cipla’s shares rose by 1.02 percent to close at Rs 901.85 apiece.
You may also read this:
IIT-Bombay and UIDAI join hands to develop touchless biometric system
Honorable Minister of Environment Bhupender Yadav have announced the inclusion of Shekha Jheel Bird Sanctuary…
India's economy is expected to grow at the 6.4% in 2026 and 6.6% in 2027…
The government has proposed the increasing the minimum distance between the new sugar mills from…
Noted pediatrician and the former Rajya Sabha member Dr Gopalrao Patil has passed away on…
India's seafood exports have reached the all-time high of ₹72,325.82 crore in the FY 2025-26…
A new global assessment by the UNESCO has revealed the concerning reality. In which nearly…